Skip to main navigation Skip to search Skip to main content

Proteomic signatures of COVID-19 Post-Vaccination/Post-Infection Syndrome (PV/PIS): insights into immune dysregulation and coagulopathy

  • Maxine Waters
  • , Mare Vlok
  • , Elouise E Kroon
  • , Maritha J Kotze
  • , Kelebogile E Moremi
  • , Sunday O Oladejo
  • , Kanshukan Rajaratnam
  • , Jean M Nunes
  • , Chantelle Venter
  • , Chantelle J Scott
  • , Douglas B Kell
  • , Etheresia Pretorius*
  • *Corresponding author for this work
  • Stellenbosch University
  • University of Liverpool

Research output: Contribution to journal › Journal article › Research › peer-review

4 Downloads (Orbit)

Abstract

During the global rollout of COVID-19 vaccines, a subset of individuals reported persistent symptoms following vaccination, with clinical presentations overlapping those of Long COVID and requiring individualised treatment strategies. Distinguishing between vaccine-related adverse events and post-infectious sequelae is challenging, particularly given the potential for unrecognised asymptomatic or mild SARS-CoV-2 infection before or after vaccination. To address this complexity, we defined our disease cohort as individuals experiencing persistent symptoms ( ≥ 12 weeks) following SARS-CoV-2 vaccination, without a confirmed history of prolonged symptoms after acute infection; for clarity, we refer to this group as presenting with Post-Vaccination/Post-Infection Syndrome (PV/PIS). In this study, we conducted a plasma proteomic analysis of digested microclot deposits isolated from platelet-poor plasma samples of 14 individuals with PV/PIS compared to 16 healthy controls, using liquid-chromatography-mass spectrometry. We identified significant alterations in coagulation factors, acute phase proteins, and immune response modulators in the PV/PIS group compared to controls. Notably, elevated levels of serum amyloid A1 and A2, attractin, and coagulation factors X and XI were observed, alongside downregulation of immune-regulatory proteins. These findings suggest that PV/PIS is characterised by persistent immune dysregulation and coagulopathy. This proteomic signature was found to only partially overlap with that previously reported in a proteomics analysis on Long COVID samples, collected prior to vaccination availability. Our results highlight the complex interplay between immune activation, endothelial dysfunction, and coagulation pathologies in PV/PIS, with distinct differences detected between these systems in Long COVID and PV/PIS, paving the way for more targeted protein research in these conditions.
Original languageEnglish
Article number1753348
JournalFrontiers in Cellular and Infection Microbiology
Volume16
ISSN2235-2988
DOIs
Publication statusPublished - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • SARS-CoV-2
  • COVID-19 Vaccines
  • Post-Infectious Disorders
  • Adult
  • Aged
  • Blood Coagulation Disorders
  • Chromatography, Liquid
  • Female
  • Humans
  • Male
  • Middle Aged
  • Vaccination
  • Proteome
  • Proteomics
  • Long COVID
  • PV/PIS
  • heterogenous amyloid deposits (microclots)
  • inflammatory molecules

Fingerprint

Dive into the research topics of 'Proteomic signatures of COVID-19 Post-Vaccination/Post-Infection Syndrome (PV/PIS): insights into immune dysregulation and coagulopathy'. Together they form a unique fingerprint.

Cite this